As well as providing insights into MLL-AF4 function in a human fetal cell context, CRISPRMLL-AF4+ ALL provides a preclinical model for translational studies that specifically recapitulates poor prognosis infant-ALL. This evidence concerns the gene AFF1 and acute lymphoblastic leukemia.